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Dear Sir, 
Extracellular adenine nucleotides regulate a broad range of physio-
logical cellular responses through G-protein-coupled P2Y receptors
and ligand-gated P2X ion channels, operating on different scales of 
time and distances (1). Platelet P2 receptors have been identified to
consist of three representatives, namely P2Y1, P2Y12, and P2X1 (2).
ADP, acting at P2Y1 and P2Y12, has been recognized as an important
mediator of primary haemostasis (2). Coactivation of both P2Y1 and
P2Y12 is necessary for normal ADP-induced platelet aggregation. The
Gq protein-coupled P2Y1 receptor is responsible for platelet shape
change through mobilization of Ca2+ from intracellular stores and for
the initiation of platelet aggregation, whereas P2Y12, targeted by speci-
fic antithrombotic drugs, leads to adenylate cyclase inhibition through a
Gi protein, completing and amplifying platelet responses to ADP. 
In contrast, ATP has commonly been regarded as a platelet inhibitor
due to its antagonistic action at the platelet P2Y receptors for ADP. 
However, because ATP, which is co-released with ADP from platelet
dense granules during platelet activation, activates the P2X1 ion chan-
nel allowing entry of extracellular Ca2+ (3), the purely antagonistic
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Fig. 1 Light transmission recordings in hirudinized PRP containing 1U/ml apyrase. Platelet shape change was induced by 0.5 M HPLC-purified ,-meATP
(A) or 1 M HPLC-purified ADP (B), in the presence of increasing concentrations of A2P5P, as indicated. Arrows show the time of addition of agonists. Percen-
tage light transmission as well as time bars are specified. The curves are representative of at least 3 independent experiments performed on different individuals.
Aggregation is prevented by the simultaneous presence of the neutralizing monoclonal anti-GPIIb/IIIa antibody MA-16N7C2 (50 g/ml) (11) C. Averaged peak
currents measured in P2X1-expressing Xenopus oocytes stimulated with 100 M ,-meATP (n = 13) alone or in the presence of 400 M A2P5P (n = 11). Data
are represented as the mean ± SEM and are expressed as percentage of the peak current induced by ,-meATP within the same batch of oocytes (*: p< 0.05)
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view of ATP in haemostasis has been questioned. Recent findings 
indeed indicate that P2X1 mediates reversible platelet shape change (4),
but also is involved in platelet shape change and aggregation induced
by collagen (5). The concept of P2 receptor activation in human plate-
lets would thus rely both on ATP-mediated fast signaling through the
P2X1 channel, and on ADP activation of the P2Y1 and P2Y12 receptors.
Pharmacological classification of P2Y and P2X receptors and 
unambigous definition of their physiological roles have long been prob-
lematic due to lack of selective receptor antagonists. Although selec-
tive antagonists now exist that discriminate between P2Y1 and P2Y12,
selective blockade of platelet P2X1 is still complicated. Notably, 
the P2Y1 antagonist, N6-methyl-2’-deoxyadenosine-3’,5’-biphosphate
(MRS 2179) (6), acting as an antiplatelet agent, has also been reported
to be an antagonist of P2X1 in vitro (7). The adenine nucleotide deriva-
tives, adenosine 3’-phosphate 5’-phosphosulfate (A3P5PS), adenosine
3’, 5’-diphosphate (A3P5P), and adenosine 2’, 5’-diphosphate (A2P5P)
are competitive antagonists at the human P2Y1 receptor stably expres-
sed in 1321N1 astrocytoma cells (8). Because these compounds are 
inactive at Gi protein-coupled P2Y receptors, they are widely used for
the analysis of the Gq protein-coupled P2Y1 receptor function in plate-
let activation without affecting P2Y12 (2). For instance, the involvement
of P2Y1 in the initiation of platelet aggregation elicited by low con-
centrations of U46619 or thrombin, known to depend on ADP release,
has been demonstrated through the inhibitory effect of A2P5P (9). 
However, whether these molecules affect the platelet P2X1 receptor
function is unknown. 
We have investigated the effect of A2P5P on the quickly reversible
platelet shape change induced by the selective P2X1 agonist,
,-methylene adenosine 5’-triphosphate (,-meATP). It appeared
that a 1 min-pre-incubation of the platelets with A2P5P dose-depen-
dently inhibited platelet shape change evoked by 0.5 M ,-meATP,
inhibition being almost complete at 400 M A2P5P (Fig. 1A). This
concentration of A2P5P fully prevents the ADP-induced platelet shape
change through P2Y1 (Fig. 1B). Accordingly, upon heterologous 
expression of P2X1 in Xenopus oocytes (10), 400 M A2P5P could 
reduce the peak amplitude current evoked by 100 M ,-meATP to
35,74 ± 14 % (p = 0.019) of its initial value (mean peak currents = 0.805
± 0.162 A, n = 13 versus 0.2877 ± 0.1129 A, n = 11 in the presen-
ce of A2P5P) (Fig. 1C). These data thus indicate that the P2Y1 antago-
nist A2P5P, previously described to be specific, exhibits non-selective 
antagonism at recombinant and human platelet P2X1 receptors.
The non-selective inhibitory effect of A2P5P on P2X1 activity has
probably hampered correct evaluation of the contribution of the P2X1
ion channel to platelet activation by many authors. This phenomenon,
added to the difficulties to preserve fast-desensitizing P2X1 responses
during platelet preparation, may partly explain why these authors have
often considered the role of this receptor in platelets to be elusive. 
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Dear Sir,
Genetic polymorphisms of angiotensin converting enzyme (I/D) 
(1, 2) and endothelial nitric oxide synthase (T(-788)C) (3, 4) have 
been proposed as potential genetic factor for myocardial infarction
(MI).
Despite numerous studies, the roles of these polymorphisms as a
clinically relevant, inherited risk factor for MI are still controversial.
The purpose of the present study is to assess the significance of these
polymorphisms by employing a large epidemiological cohort as a con-
trol population. The study population consisted of 454 subjects with MI
recruited from the National Cardiovascular Center, and 3918 subjects
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